DECREE OF THE HEAD OF DRUG AND FOOD SUPERVISORY AGENCY
NO. HK.00.05.3.1950

CONCERNING
CRITERIA AND PROCEDURES OF DRUG REGISTRATION

BY GRACE OF THE ALMIGHTY GOD
THE HEAD OF DRUG AND FOOD SUPERVISORY AGENCY,

Considering:

• a. that in order to protect the public from the drug that do not fulfil the criteria of drug efficacy. Safety, quality and public health need, it is necessary to execute drug evaluation under the regulation of drug registration prior to marketing.
• b. that several provision in drug regulation were no longer suitable with the development of science and technology, therefore it is necessary to review and to re-regulate the procedures of drug registration and evaluation;
• c. that in the framework of entering the era of globalization and harmonization in the pharmaceutical field, the regulation of drug registration must be improved;
• d. that based on the consideration in a, b and c, it is necessary to stipulate the Decree of the Head of the Drug and Food Supervisory Agency concerning the Criteria and the Procedure of Drug Registration.

In View of:

• 1. Law of Prescription Drugs (Statute Book No. 419/1949);
• 2. Law No. 23/1992 concerning Health (Statute Book No. 100/1992, Supplement to Statute Book No. 3495);
• 3. Law No. 5/1997 concerning Psychotropic (Statute Book No. 10/1997, Supplement to Statute Book No. 3671).
• 4. Law No. 22/1997 concerning Narcotics (Statute Book No. 67/1997, Supplement to Statute Book No. 3698)
• 5. Law No. 8/1999 concerning Consumer Protection (Statute Book No. 42/1999, Supplement to Statute Book No. 3821).
• 6. Government Regulation No. 17/2001 concerning Tariff of Non-Taxes of State Income applied in the Drug and Food Supervisory Agency.
• 7. Presidential Decree No. 103/2001 concerning Position, Task, Function, Authority, Organizational Structure and Working Arrangement of Non Ministerial Government Agency as amended by the Presidential Decree No. 46/2002.
• 8. Presidential Decree No. 110/2001 concerning Unit of Organization and the Task of First Echelon State employees of Non Ministerial Government Agency as amended by Presidential Decree No. 48/2002.
• 9. Regulation of the Minister of Health No. 949/MENKES/PER/VI/2000 of 2000 concerning Drug Registration.
• 10. Decree of the Head of Drug and Food Supervisory Agency No. 02001/SK/KBOOM/2001 concerning Organization, Working Arrangement of Drug and Food Supervisory Agency;
• 11. Decree of the Head of Drug and Food Supervisory Agency No. 02002/SK/KBPOM/2001 concerning Procedure of Clinical Trial Procedures;
• 12. Decree of the Head of Drug and Food Supervisory Agency No. HK.00.05.3.00914/2002 concerning Special Access on Importing Drugs.

DECIDES:

To Stipulate:

THE DECREE OF THE HEAD OF DRUG AND FOOD SUPERVISORY AGENCY ON CRITERIA AND PROCEDURES OF DRUG REGISTRATION.

CHAPTER I
GENERAL PROVISION

Article 1

In this Decree:

• 1. Registration is a procedure of drug registration application and drug evaluation in order to obtain distribution license.
• 2. Distribution license is an official approval on drug registration for the purpose of marketing a pharmaceutical product in Indonesia.
• 3. Therapeutic Products are any preparations or combination of ingredients including drug, biological product and other preparations which are intended to modify or explore physiological system or pathological states for diagnosing, treatment, recovery and health improvement.
• 4. Drug is any pharmaceutical product including biological product which is composed of active ingredient, including contraceptives and other preparations containing medicine.
• 5. Narcotic is ingredient or drug derived from herbs or non herbal, either synthetic or non synthetic, which may inhibit or affect consciousness, induce anaesthesia, alleviate to relieve pain.
• 6. Psychotropic is ingredient or drug, either natural or synthetic non-narcotics, which act psycho-active selectively affecting central nervous system which may induce specific changes to mental activities and behaviour.
• 7. Biological products are vaccine, antibody, antigen, hormone, enzyme, blood product and other fermentation product (including monoclonal antibody and products derived from recombinant DNA technology) which are used to modify or explore physiological and health improvement).
• 8. Contraceptives are drugs or devices which are intended for prevention of conception.
• 9. New drug or new finished drug is a drug which new active ingredient or composition or dosage from/route of administration or indication or posology which has not been approved in Indonesia.
• 10. Copy drug or equal drug is a drug which contain same active ingredient to a registered drug.
• 11. Domestically manufactured product is a drug which is domestically manufactured and packaged by industry in Indonesia.
• 12. Contracted drug is drug which manufacturing is delegated to other pharmaceutical industry.
• 13. License drug is a drug which is manufactured under license.
• 14. Imported drug is drug which is manufactured by overseas pharmaceutical industry.
• 15. Patent protected drug is drug which has obtained patent protection based on valid Patent Law in Indonesia.
• 16. Counterfeit drug is drug which is produced by an unauthorized party, against the prevailing regulation or drug manufacturing using similar identity or labelling of other drug which has had a distribution license.
• 17. Contracting party is a pharmaceutical industry or other institution which has delegated a drug manufacturing activity based on a contract.
• 18. Contractor is a pharmaceutical industry whish has accepted a drug manufacturing project based on a contract.
• 19. Licensing is delegation of right and authorization to use the research and development related to the transfer of technology in manufacture, utilization of research and development on efficacy, safety, quality and the use of trade name and marketing of a drug.
• 20. Labelling is a complete information on drug, efficacy, safety, way to use and other information which are considered important to be put on the label, brochure and carton of a drug packaging.
• 21. Marketing is all activities in drug distribution channels or delivery related to trade, non trade or delivery service.
• 22. Floppy disk is specific formatted disk for drug registrations.
• 23. Distribution license status document is an official document on drug status in a country which is issued by the drug regulatory authority, such as Certificate of Free Sale (CFS) and Certificate of Pharmaceutical Product (CPP).
• 24. FERO (Electronic Facility for Drug Registration) is an electronic facility that support drug registration system in a harmonized way, mainly to access data monitoring and registration process.
• 25. STINEL (Electronic Information Standard) is standard of a complete information on drug, efficacy, safety, way to use, and other information that must be submitted in the form B26-12.
• 26. Formula is a qualitative and quantitative composition of active and inactive ingredient in a drug.
• 27. Form is a drug registration form.
• 28. Drug strength is the concentration of active Ingredient in a drug.
• 29. Composition is the qualitative and quantitative composition of active ingredient in a drug.
• 30. Independent Assessment Report is a critical summary and interpretation of the data, with conclusions, prepared by on behalf of the drug regulatory authority in the country of a marketed drug and the result is not based on evaluation result of other country.
• 31. Applicant is a pharmaceutical industry or a pharmaceutical wholesaler which has received a business license in compliance to the prevailing regulation.
• 32. Unit pack is a smallest pack with label in compliance to the regulation.
• 33. Established evaluation system is evaluation system which is conducted in stages, and with method of evaluation in compliance to international standard by team or independent committee, who is authorized in a country recognized as innovated country.
• 34. Variation is a change to any aspect of therapeutic product including but not limited to a change to formulation, method and site of manufacture, specifications for finished product and ingredients, container, packaging, labelling, and product information.
• 35. Active pharmaceutical ingredient (API) is a compound that is intended to be used in the manufacture of a pharmaceutical product as a therapeutically active compound (ingredient).
• 36. Inactive Ingredient is component of drugs that are meant as filter, solvent, coating, propellant and ingredient to enhance drug usage, forming, preservative or as colouring agent non pharmacologically effective.
• 37. Blood product is a product derived from the component of blood or other blood component.
• 38. Blood Component is a component which is physically isolated from other blood component.
• 39. The Head of Agency is the head of the Drug and Food Supervisory Agency the Republic of Indonesia.

Article 2

(1) Therapeutic product that has been marketed in the territory of Indonesia and/or aims to be exported must have a distribution license.

(2) In order to obtain a distribution license as intended in paragraph (1), the applicant should submit a registration application.

CHAPTER II
DRUG CRITERIA

Article 3

(1) In obtaining drug distribution license, a drug should fulfil the below main criteria:

• a. Convincing evidence of efficacy, and adequate safety, proven through pre-clinical and clinical trials or other proof in accordance with development in the relevant scientific knowledge.
• b. Having quality that fulfils the criteria concerning the production process in accordance with Good Manufacturing Practice of (GMP/CPOB), specifications and method of analysis of all materials used in the finished product with proven documents.
• c. Labelling must contains objective and complete information which must ensure, rational and safe use of drugs.

(2) Besides the criteria as intended in paragraph (1) other below criteria should also be fulfilled:

• a. Specifically or new psychotropic should have superiority in efficacy and safety compared to the standard drug and other marketed drugs in Indonesia for the claimed indication.
• b. Specific contraceptives applied or the National program and other drugs for other National program, that will be decided later, should perform a clinical trial in Indonesia.
• c. In conformity with the public health need.

(3) The criteria for the public health need and affordability of the society as intended in paragraph (2) c, is stipulated separately by the Head of Agency.

CHAPTER III
APPLICANT

Part one
Applicant of Domestically Manufactured Products

Article 4

(1) Domestically manufactured products include drug without license, drug under license and contracted drug.

(2) Applicant of drug without license, drug under license as intended in paragraph (1) are pharmaceutical industry from license or at least a principle license for pharmaceutical industry from the Head of Agency or an approval from foreign capital investment board.

(3) Pharmaceutical industry as intended in paragraph (1) has an obligation to fulfil the CPOB criteria.

(4) Applicant of Contracted drug as intended in paragraph (1) is a contracting party which is a pharmaceutical industry or other agency.

(5) The provision on the criteria for other agency as contracting party as intended in paragraph (4) is stipulated separately by the head of agency.

Part Two
Applicant of Imported Drugs

Article 5

(1) Applicant of imported drug is a domestic pharmaceutical industry or pharmaceutical wholesaler which has obtained a written appointment letter from an overseas pharmaceutical industry or product owner.

(2) Overseas pharmaceutical industry as intended in paragraph (1) oblige to fulfil the CPOB criteria which must be proven by appropriate documents or if it is deemed necessary to be inspected locally b an authorized GMP inspector.

(3) Provision on the inspection procedure as intended in paragraph (2), is stipulated separately by the Head of Agency.

Part Three
Applicant of Drug for Export Only

Article 6

(1) Applicant of drug for export only should be a pharmaceutical industry.

(2) Drugs for export only as intended in paragraph (1) should fulfil the criteria as intended in Article (3), unless accompanied by a written approval from the destination country.

Part Four
Applicant of Patent Protected Drug

Article 7

(1) Applicant of patented drugs in Indonesia is a domestic pharmaceutical industry as patent holder, or other pharmaceutical industry or pharmaceutical wholesaler which has obtained a patent transferred from the patent holder following the valid patent provision in Indonesia.

(2) Patent ownership as intended in paragraph (1) should be proven with a patent certificate.

(3) Patent transfer as intended in paragraph (1) should be proven by a proof of transfer following the valid provision.

Part Five
Responsibility of the applicant

Article 8

(1) The Applicant is responsible for:

• a. The completeness of the submitted documents.
• b. The truth of all information which is stated in the registration documents.
• c. The truth and validity of documents which are attached to support the registration.
• d. Revisions and additional data and information on the product that is in the process of registration or has already had a distribution license.

(2) Each revision as intended in paragraph (1) d should have an approval from the Head of Agency.

CHAPTER IV
CLASIFICATION AND CATEGORY OF DRUG REGISTRATION

Part One
Classification of Drug Registration

Article 9

(1) Drug is classified into therapeutic class.

(2) Therapeutic class as intended in paragraph (1) is based on the classification on Anatomical Therapeutic Chemical (ATC).

Part Two
Category Drug Registration

Article 10

(1) Drug registrations are categorized into registration of new and registration of drug variations.

(2) New drug registration as intended in paragraph (1) consist of:

• a. Category 1: is new drug registration with new active pharmaceutical ingredient or new derivative or new combination or biological product with new active ingredient or new combination or in a new dosage form;
• b. Category 2: is new drug registration with old composition in a new dosage form or new strength or similar biological product;
• c. Category 3: is registration of drug or biological product with old composition with:
• 3.1. new indications
• 3.2. new posology
• d. Category 4: is registration of copy drug:
• 4.1. copy drug with a trade name
• 4.2. copy drug with a generic name
• e. Category 5: is registration of other preparation containing drug

(3) Registration of drug variation as intended in paragraph (1) consists of:

• a. Category 6: is registration of copy drug which has already obtained a distribution license with a modification from what has already been approved in Indonesia:
• 6.1. Modification or addition of dosage form with different posology or route of administration.
• 6.2. Modification or addition of dosage form
• 6.3. Modification or addition of drug strength
• 6.4. Modification of drug composition
• 6.5. Modification of copy drug with trade name into copy drug with generic name or inverse.
• b. Category 7: is registration of drug that has obtained a distribution license with a modification of label claim which influence drug safety.
• c. Category 8: is registration of drug which has obtained a distribution license with:
• 8.1. Modification of inactive ingredient.
• 8.2. Modification of the specifications and/or method of analysis.
• 8.3. Modification of stability.
• 8.4. Modification of the technology of production and/or manufacturing site.
• d. Category 9: is registration of drug that has obtained a marketing with a modification or addition to the packaging;
• e. Category 10: is registration of drug that has obtained a distribution license with:
• 10.1. Modification of the label claim which shall not influence the efficacy, safety and quality.
• 10.2. Modification of packaging design.
• 10.3. Change of factory name or the name of license-holder.
• 10.4. Change of importer.
• 10.5. Modification / addition of package size.
• 10.6. Change of trade name without any change of formula and package form/type.

CHAPTER V
POCEDURE FOR OBTAINING A DISTRIBUTION LICENSE

Part One
General

Article 11

(1) Drug registration shall be submitted by the applicant to the Head of the Agency.

(2) Drug registration consist of 2 (two) stages, that is pre-registration and submission of the registration documents.

(3) Submission of the registration documents as intended in paragraph (2) is conducted by using registration forms and floppy disks, completed with supporting documents following valid provisions.

(4) Registration data, related to evaluation and analysis of drug is confidentially protected by the Head of Agency.

Part Two
Pre-Registration

Article 12

Pre-registration is a registration procedure that is conducted to decide the evaluation Path and the completeness of drug registration documents for category 1, category 2, category 3, category 4, category 5, category 6, and category 7 as intended in Article 10.

Article 13

(1) Pre-registration application must contain documents as stipulated in Attachment 2 and completed with the search result of drug trade name.

(2) Pre-registration documents as intended in paragraph (1) will be used to consider the evaluation Path accordance with Attachment 3 and must be completed with administrative documents as stipulated in Attachment 4.

(3) Criteria for evaluation Path as stipulated in paragraph (2) must comply with Attachment 5 and if it is deemed necessary completed with the details of independent assessment report following Attachment 6.

(4) Drug name meant in paragraph (1) night be a generic name or a trade name based on General Guideline of Drug Name following Attachment 7.

Article 14

The result of pre-registration will be communicated to the applicant in writing and it is binding.

Part Three
Registration Application

Article 15

(1) Registration application is conducted by submitting registration documents, than is by completing registration form and floppy disk and attaching the receipt of payment of evaluation and registration fee and the result of pre-registration.

(2) Registration form or floppy disk as intended in paragraph (1) shall be supplied by the directorate of Drug and Biological Product Evaluation.

Article 16

(1) Upon Drug Registration, applicant is obliged to pay evaluation fee.

(2) Evaluation fee as intended in paragraph (1), is in conformity with the provisions of Government Regulation on the Tariff of a type of non tax state income (PNBP) valid to Drug and Food Supervisory Agency.

Article 17

(1) For the purpose of evaluation on quality, applicant should submit drug sample for 3 (three) times of analysis and standard raw material conform to the specification and method of analysis of the active ingredient of the objective drug.

(2) Copy drug is an exception of the provisions as intended in paragraph (1), submission of drug sample and standard raw material will be requested, if deemed necessary.

(3) The executions of the submission of drug sample and standard raw material as intended in paragraph (1) and paragraph (2) will be stipulated separately by the Head of Agency.

Article 18

Registration of contracted drug, drug under license, and imported drug, beside follows the provisions of drug registration, also should follow to the provisions in Attachment 8.

Part Four
Registration Dossier

Article 19

(1) Registration documents as intended in Article 15 paragraph (1) consists of registration forms with the administrative documents and supporting documents.

(2) Administrative document as mean in paragraph (1) is the document that must be fulfilled for drug registration in line with Attachment 4.

Article 20

Supporting documents as intended in Article 19 paragraph (1) consist of:

• a. Quality and technology documents to ensure the quality of drug conforms to Attachment 9;
• b. Pre-clinical trial documents which should describe the profile of pharmacodynamic, pharmacokinetic as well as safety level for toxicity, before the human clinical trial, which conforms to the stipulation in Attachment 10 and pre-clinical trial report matrix following to Attachment 11.
• c. Clinical trial document should be able to prove convincingly the efficacy and safety of finished drug in compliance to the stipulations in Attachment 12 and the clinical trial report matrix conform to Attachment 13.

Article 21

(1) Registration form as intended in Article 19 paragraph (1) should be completed with:

• a. Package design artwork that includes label, box/outer package, strip/blister, catch cover, ampoule/vial, and other package conform to the provisions on the packaging and valid label acts, which represent a drug package design which will be marketed and should be completed with colour design.
• b. Brochure which represent a drug information.

(2) Package design artwork as intended in paragraph (1) a specification for generic drug, follow provisions on the standard specifications of generic drug.

(3) Minimum information that should be printed on the package design as intended in paragraph (1) a and paragraph (2) should follow to the stipulation in Attachment 14.

(4) Minimum information that should be printed on the brochure as intended in paragraph (1) b should follow to the stipulation in Attachment 15.

Article 22

(1) For new registration as intended in the Article 10 paragraph (2), the submitted documents should consist of floppy disk that has been completed following the data in Form A and form of Forms A, Form B1, Form B2, Form B3, Form B4, Form C1, Form C2, Form C3, Form D, and supporting documents for new registration for each category following Attachment 16.

(2) Registration documents of copy drug with an active ingredient that has already been available in the Electronic Information Standard (STINEL), consist of floppy disk with the data in Form A and Form B21-13, and documents of Form A, Form B1, Form B214, Form B4, Form C1, and Form D.

(3) Registration documents of copy drug with an active ingredient that has no STINEL, consist of a floppy disk with the data in Form A and Form A, Form B1, Form B2, Form B3, Form C1, and Form D.

Article 23

For registration drug variations as intended in Article 10 paragraph (3), the submitted documents consist of a floppy disk which has been completed following data in Form A and the forms and supporting documents for registration of drug variations as stipulated in Attachment 17.

Part Five
Forms

Article 24

(1) Registration forms as intended in Article 19 consists of:

• a, Form A contains information about name and address of the applicant and manufacturing pharmaceutical industry and general information about drug to be registered.
• b. Form B Contains documents that cover the aspects of efficacy, safety and the quality of registered drug and is binding, such as Form B1 (administrative documents), Form B2 (product information that cover the aspects of efficacy, safety and quality), Form B3 (the procedure of Batch numbering system) and Form B4 (price information);
• c. Form C contains documents that must be attached to support the information mentioned in Form B2, that is Form C1 (documents on quality and technology), form C2 (preclinical trial documents) and Form C3 (clinical trial documents);
• d. Form D contains a list of the submitted drug sample and its reference standard.

(2) Registration forms as intended in paragraph (1) following Attachment 18.

Part Six
Forms Completion

Article 25

(1) Completion of registration forms and registration documents should follow the below provisions:

• a. Completion of registration forms should be in Indonesian or in English;
• b. Registration documents can be in Indonesian or in English;
• c. Labelling of over the counter drug/limited over the counter drug must be in Indonesian;
• d. Labelling of drugs for export only should at least be in English.

(2) Guideline for the completion of registration forms conform to Attachment 19.

(3) In completing registration forms as intended in paragraph (2), the description of active and inactive ingredients must conform to Attachment 20.

Part Seven
Evaluation

Article 26

(1) Toward drug registration documents which has fulfilled the provision as intended in Article 15 and Article 16, shall be evaluated in compliance with the provisions as intended in Article 3.

(2) Evaluation as intended in paragraph (1) shall be grouped into new drug and biological product evaluation and copy drug evaluation.

(3) The execution of evaluation for new drug registration is proceed through Path I (one), Path II (two) or Path III (three).

Article 27

(1) Drugs that will be evaluated through path I (one) are:

• a. Drugs that are indicated for the treatment/therapy of serious diseases and life-threatening diseases in human;
• b. Generic essential drugs for public health program.

(2) Drugs as intended in paragraph (1) are stipulated by the Head of Agency.

Article 28

Drugs that will be evaluated through Path II (two) are:

• a. New drug which has been approved in the group of countries that applied harmonization of evaluation system and 1 (one) county that has applied established evaluation system which is supported by an independent assessment report;
• b. New Drug which has been approved in 3 (three) countries that applied established evaluation system supported with independent assessment report.
• c. Copy drug without STINEL and blood products.

Article 29

Drugs that are not included in Article 27 and Article 28 will be evaluated through Path III (three).

Article 30

(1) For the execution of evaluation, a national Committee on Drug Evaluation (KOMNAS POJ) has been founded.

(2) Organization, Task and Functions of KOMNAS POJ as intended in paragraph (1) are stipulated separately by the Head of Agency.

Article 31

(1) In case of further requirement of additional data for evaluation, the head of the National Agency will issue a written request by using a format conform with Attachment 21.

(2) Applicant is obliged to submit additional data as intended in paragraph (1) within 120 (one hundred and twenty) days from the date of letter issuance.

(3) In case of applicant was unable to fulfil the provisions as intended in paragraph (2) the Head of Agency will issue a letter of rejection of the registration by using a format conform with Attachment 22.

(4) In case of registration that is rejected as intended in paragraph (3), the applicant can resubmit a new registration with the documents as intended in Article 15 and completed with additional data as intended in paragraph (2).

Article 32

The result of efficacy and safety from KOMNAS POJ (National Committee of Drug Evaluation) will be informed in written form to the applicant with a format conform with Attachment 23.

Part Eight
Decision Issuance

Article 33

(1) Based on the recommendation of KOMNAS POJ, the Head of the National Agency will issue a decision form distribution license by using a format which following Attachment 24 or will reject by using a format conform with Attachment 25.

(2) The timelines for decision issuance as intended in paragraph (1), will be issued after receiving complete registration documents:

• a. New registration Path I (one): 100 working days;
• b. New registration Path II (two): 150 working days;
• c. New registration Path II (three) for new drug: 300 working days; copy drug with STINEL and drug for export only: 80 working days;
• d. Registration of drug variation category-6, category-7,category-8 and category-9: 80 working days;
• e. Registration of drug variation category-10 with latest information of labelling: 40 working days.

Part Nine
Hearing

Article 34

(1) In case of any objection upon/toward the result of efficacy and safety evaluation from KOMNAS POJ as intended in Article 32, applicant could submit a written application for hearing to the Head of Agency.

(2) The application as intended in paragraph (1) should be submitted within 15 working days from date of issuance letter of the result of efficacy and safety evaluation.

Part Ten
Appeals

Article 35

(1) In case any objection upon rejection of a registration as intended in Article 33 paragraph (1), applicant could submit a written request for appeals to the Head of Agency.

(2) Appeals as intended in paragraph (1) should be submitted within 6 months from the rejection date and the applicant can obtain two chances of appeals.

(3) Appeals should be completed with new data and/or the data that has ever been submitted with accomplishment of justification.

Part Eleven
Resubmission of Drug Registration

Article 36

In case of the rejection of registration for the reason of safety and efficacy, resubmission may be applied after 1 (one) year from the date of rejection.

Part Twelve
Issuance of Distribution license

Article 37

(1) Distribution license as intended in Article 33 paragraph (1) is granted only to the applicant that fulfil the criteria of:

• a. Administration;
• b. Technical, presented as the result of evaluation on efficacy, safety, quality, usefulness and labelling.

(2) Distribution license will be valid for 5 (five) years and should fulfil the valid provisions.

(3) Renewal of drug distribution license is stipulated separately by the Head of Agency.

CHAPTER VI
EXECUTION OF DISTRIBUTION LICENSE

Article 38

(1) Applicant which has obtained distribution license obliged to produce or import or distribute drug within 12 (twelve) months after the approval date issuance.

(2) Execution of activities as intended in paragraph (1) should be reported and submit the marketed unit pack to the Head of Agency.

(3) Submission of ready to distribute marketed unit pack as intended in paragraph (2) shall be executed at least within 1 (one) month before the implementation of production, import or drug distribution.

(4) Pay annual fee of distribution license in compliance with the valid provisions.

(5) Annual fee as intended in paragraph (4) is stipulated separately by the Head of Agency.

Article 39

(1) Execution of drug import must be completed with Certificate of Analysis for each batch.

(2) Execution of vaccine for domestic distribution and export should obtain a Certification of batch release by the Head of Agency.

(3) Execution of vaccines imported should obtain a Certification of Batch Release by the Head of Agency or Authorized Agency Staff from the original county where production take place.

(4) Import of narcotic and psychotropic containing drug execution are stipulated separately by the Head of Agency.

CHAPTER VII
RE-EVALUATION

Article 40

(1) The drug that has been granted distribution license can be re-evaluated/have periodic reviews by the Head of Agency.

(2) Re-evaluation on a marketed drug will be done upon:

• a. Post marketing surveillance revealed that the risk of the drug adverse effect out weight the drug efficacy.
• b. Drugs with efficacy that is not better than placebo.
• c. Drugs that failed the criteria of bioavailability/bioequivalence.

(3) Upon drug which is re-evaluated as intended in paragraph (2) pharmaceutical industry/applicant is obliged to withdraw this drug from the market.

(4) Re-evaluation is also applicable for the improvement of composition and drug formula.

CHAPTER VIII
WITHDRAWAL OF DISTRIBUTION LICENSE

Article 41

The Head of Agency may cancel distribution license by using a format conform with Attachment 26, in case of one of the below:

• a. Based on the investigation or monitoring of drug usage after market distribution, the drug failed to fulfil the criteria as intended in Article 3;
• b. Labelling and promotion deviated from distribution license;
• c. Not complying with the obligation as intended in Article 38;
• d. If during the sequence 12 (twelve) months the drug has not been manufactured, imported or distributed.
• e. The license of applicant pharmaceutical industry or pharmaceutical wholesaler that registers, manufacture, or distribute the drug has been cancelled.
• f. Owner of distribution license do violation in production and/or distribution of drug.

CHAPTER IX
SANCTIONS

Article 42

The applicants who manufacture and/or distribute counterfeit drug will receive a sanction following the provisions of valid rules of law.

Article 43

(1) Any individual who distribute finished drug that is not in compliance with the provisions in this decree, will be sanctioned with a punishment following provisions of valid rules of law.

(2) Beside a sanction of punishment as intended in paragraph (1), an administrative sanction will be executed in the form of:

• a. Written warning;
• b. Temporary suspension of activities;
• c. Withdrawal of distribution license;
• d. Other administrative sanction following the valid rules of law.

CHAPTER X
TRANSITIONAL PROVISIONS

Article 44

All provisions on the rules of law concerning the procedure of drug registration already issued before the stipulation of this decree, shall remain valid as long as they are not contradiction and/or being substituted with the provisions of this decree.

Article 45

This decree effective as of the date of stipulation and shall be amended and improved if in future a revision is needed.

For public cognizance, this decree shall be published in the Statute Book of the Republic of Indonesia.

Stipulated in Jakarta
On May 14, 2003
Head of Drug and Food Supervisory Agency
signed,
H. SAMPURNO